SoylentNews

Arthur T Knackerbracket has found the following story:

A recent analysis reveals that treatment of male breast cancer has evolved over the years. In addition, certain patient-, tumor-, and treatment-related factors are linked with better survival. The findings are published early online in CANCER, a peer-reviewed journal of the American Cancer Society.

Male breast cancer (MBC) comprises one percent of all breast cancer cases, yet no prospective randomized clinical trials specifically focused on MBC have been successfully completed. Some studies suggest that the incidence of MBC may be rising, however, and there is an increasing appreciation that the tumor biology of MBC differs from that of female breast cancer.

To examine how MBC has been treated in the United States in recent years, and to identify factors associated with patient prognosis, a team led by Kathryn Ruddy, MD, MPH, and Siddhartha Yadav, MBBS, at Mayo Clinic in Rochester, analyzed information from the National Cancer Database on men diagnosed with stage I-III breast cancer between 2004 and 2014.

[...] Factors associated with worse overall survival were older age, black race, multiple comorbidities, high tumor grade and stage, and undergoing total mastectomy. Residing in higher income areas; having tumors that express the progesterone receptor; and receiving chemotherapy, radiation, and anti-estrogen therapy were associated with better overall survival.

Journal Reference:

“Male breast cancer in the United States: Treatment patterns and prognostic factors in the twenty-first century.” Siddhartha Yadav, Dhauna Karam, Irbaz Bin Riaz, Hao Xie, Urshila Durani, Narjust Duma, Karthik V. Giridhar, Tina J. Hieken, Judy C. Boughey, Robert W. Mutter, John R. Hawse, Rafael E. Jimenez, Fergus J. Couch, Roberto A. Leon Ferre, and Kathryn J. Ruddy. CANCER; (DOI: 10.1002/cncr.32472).

Original Submission